title: The issues regarding postoperative adjuvant therapy and prognostic risk factors for patients with stage I-II cervical cancer: A review.
abstract: The treatment for most patients with early-stage cervical cancer involves radical hysterectomy and pelvic lymph node dissection, and indications for postoperative adjuvant therapy have been determined by evaluating the prognostic risk factors for recurrence in each case. The aim of this review is to raise and discuss the various issues that have not yet been resolved regarding the prognostic risk factors and postoperative adjuvant therapy. Several clinicopathological factors, such as tumor size, lymphovascular space involvement, deep stromal invasion, parametrial involvement and lymph node metastasis, have been identified to have prognostic significance in early-stage cervical cancer. However, this remains controversial because there is suggested to be substantial heterogeneity among patients after radical hysterectomy and lymphadenectomy and it would be difficult to define the risk groups clearly. This indicates the need to develop more convenient and accurate criteria to define risk groups. According to the currently available evidence, patients in the high-risk group should receive adjuvant concurrent chemoradiotherapy (CCRT) with cisplatin (CDDP) and fluolouracil. However, CCRT with CDDP administered weekly (CCRT-P) has instead been applied in a clinical context worldwide. Whether CCRT-P has a survival benefit compared with radiotherapy (RT) alone is unknown because no randomized phase III trials have been performed for patients in the high-risk group after radical surgery. Patients with high-risk factors have a high incidence of distant metastasis, for whom systemic chemotherapy might be a key to improving overall survival. The pivotal study that investigated the role of RT alone for patients with intermediate-risk factors after hysterectomy is the GOG092 trial. This trial showed a 47% reduction in the risk of recurrence after RT compared with no further treatment (NFT). However, the improvement in overall survival with RT did not reach statistical significance, while patients allocated to the RT group did experience an increase in severe toxicities compared with the NFT group. This could be why many physicians are reluctant to treat patients with this approach, although guidelines recommend RT for patients with intermediate-risk factors. With regard to toxicities, postoperative RT would be problematic because the organs in the pelvis targeted by RT have already been damaged by radical surgery. To reduce the toxicities, intensity-modulated radiotherapy would best be used worldwide. Further improvement in adjuvant therapy will come from enhanced definition of prognostic risk factors, better patient selection, and refinements in both local and systematic therapies.
authors.affiliation: Shizuoka Cancer Center, Suntogun, Japan.
authors.forename: Munetaka
authors.initials: M
authors.lastname: Takekuma
authors.affiliation: Shizuoka Cancer Center, Suntogun, Japan.
authors.forename: Yuka
authors.initials: Y
authors.lastname: Kasamatsu
authors.affiliation: Shizuoka Cancer Center, Suntogun, Japan.
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Kado
authors.affiliation: Shizuoka Cancer Center, Suntogun, Japan.
authors.forename: Shiho
authors.initials: S
authors.lastname: Kuji
authors.affiliation: Shizuoka Cancer Center, Suntogun, Japan.
authors.forename: Aki
authors.initials: A
authors.lastname: Tanaka
authors.affiliation: Shizuoka Cancer Center, Suntogun, Japan.
authors.forename: Nobutaka
authors.initials: N
authors.lastname: Takahashi
authors.affiliation: Shizuoka Cancer Center, Suntogun, Japan.
authors.forename: Masakazu
authors.initials: M
authors.lastname: Abe
authors.affiliation: Shizuoka Cancer Center, Suntogun, Japan.
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Hirashima
mesh_terms: D003131:Combined Modality Therapy / Q000379:methods* / Q000592:standards; D005260:Female; D006801:Humans; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery
keywords: early-stage cervical cancer; postoperative adjuvant therapy; prognostic factors